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Background: Radical segmentectomy has been performed for small-sized non-small cell lung cancer (NSCLC).
However, underestimation of mediastinal lymph node metastasis in the absence of hilar or interlobar metastasis
(skip N2) affects surgical strategy. Our aim was to investigate preoperative and intraoperative predictors of skip N2
in clinical stage (c-stage) IA NSCLC.
Methods: From 1998 to 2011, 279 patients (155 men and 124 women) with c-stage IA NSCLC (230 pN0, 17 pN1,
12 skip N2, 20 non-skip N2) underwent systematic lobectomy (R0 resection) at our institute. We compared pre-
operative serum concentrations of carcinoembryonic antigen, cytokeratin 19 fragment, sialyl Lewis X (SLX), and pre-
and intraoperative clinicopathological features of pN0 and skip N2 patients. Receiver operator characteristic (ROC)
curve analysis was performed to distinguish between the two patient groups.
Results: The 5-year survival rate of skip N2 patients was 78.6%, higher than that of non-skip N2 patients (44.9%),
and not significantly different than that of pN0 (86.7%) or pN1 patients (82.4%). The mean serum SLX concentration
in skip N2 patients (28.0 U/ml) was elevated compared to that in pN0 patients (22.9 U/ml). In ROC analysis of SLX,
the area under the curve was 0.710, and the optimal cut-off value was 21.4 U/ml (sensitivity, 91.7%; specificity,
51.7%). In multivariate analysis, SLX was an independent predictor of skip N2 in patients with c-stage IA NSCLC
(odds ratio, 9.43; p = 0.006).
Conclusions: Skip N2 metastasis is common in patients with c-stage IA NSCLC with high serum SLX, and lobectomy
with complete dissection of hilar and mediastinal lymph nodes should remain the standard surgical procedure for
these cases.
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Lung cancer is the leading cause of cancer-related deaths
worldwide [1]. The treatment of non-small cell lung can-
cer (NSCLC) depends on the stage of the disease [2].
Lobectomy with radical lymph node dissection remains
the standard initial therapy for patients with stage I, II,
and IIIA NSCLC [3,4], but limited resection has also
been performed for early stage NSCLC. The Lung
Cancer Study Group performed a pivotal study compar-
ing limited resection (segment or wedge) with lobectomy
for clinical stage (c-stage) IA NSCLC and found inferior
overall survival and three times the local recurrence rate* Correspondence: m1364552@msic.med.osaka-cu.ac.jp
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reproduction in any medium, provided the orin the limited resection group [5]. Radical segmentect-
omy has been performed for small-sized (tumor diam-
eter ≤3 cm) c-stage IA NSCLC [6-8]. In reported studies
there was no significant difference in overall 5-year sur-
vival rates between patients undergoing segmentectomy
compared to lobectomy (75.0 to 89.8% and 81.0 to
84.0%, respectively) [6-9]. In a separate study, Whitson
et al. reported that lobectomy conferred superior un-
adjusted overall and cancer-specific 5-year survival com-
pared with segmentectomy [10]. Thus, the issue of
surgical strategy remains controversial. A phase III study
is underway in Japan to evaluate overall survival of
patients with small-sized (tumor diameter ≤2 cm)
peripheral NSCLC treated with segmentectomy versus
lobectomy (JCOG0802/WJOG4607L) [11].al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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must include negative hilar and mediastinal lymph node
metastases. If any diseased lymph node is found, seg-
mentectomy should be converted to standard lobectomy.
In some reports, segmentectomy was performed in pa-
tients with NSCLC (tumor diameter ≤2 cm) negative for
lymph node metastasis, as confirmed by frozen-section
intraoperative examination [12,13]. However, N2 lymph
node metastasis without N1 hilar or interlobar lymph
node involvement (skip N2 metastasis) might be over-
looked if segmentectomy is performed with frozen-
section examination of hilar and interlobar lymph nodes
only. It has been reported that among 275 patients with
c-stage IA NSCLC who were scheduled to undergo rad-
ical segmentectomy, 15 patients (6%) had pathologically
confirmed N1 or N2 disease, and 4 of these (27%) had skip
N2 metastasis [14]. Recently, intraoperative sentinel-node
biopsy has been performed using new methods, such as
isotope [14,15] or indocyanine green fluorescence [16] to
avoid overlooking skip N2 metastasis. Patients with skip
N2 have a better prognosis than non-skip N2 patients
(overall 5-year survival rate, 34.4 to 41.0% and 14.0 to
24.0%, respectively) when treated with lobectomy and
hilar and mediastinal lymph node dissection [17-22].
Therefore, accurate preoperative prediction of lymph node
involvement is very important in planning adequate surgi-
cal resection. Our aim was to investigate the preoperative
and intraoperative predictors of skip N2 and to recom-
mend appropriate surgical resection in small-sized (tumor
diameter ≤ 3 cm) c-stage IA NSCLC.
Methods
Two hundred seventy-nine patients (155 men and 124
women, mean age 66.2 years) with c-stage IA (tumor
diameter ≤3 cm) NSCLC underwent pulmonary resec-
tion (R0) at Osaka City University Hospital from January
1998 to December 2011. The surgical procedure per-
formed was potentially curative complete resection by
systematic lobectomy in combination with hilar and me-
diastinal lymph node dissection (over ND2a-1). When
lymph node metastases in lymph nodes number 10, 11,
and 12 were suspected intraoperatively, these lymph
nodes were examined by frozen section. Patients with
preoperative chemotherapy or radiation therapy were ex-
cluded from the study. Pathological diagnoses were per-
formed by at least two pathologists in our hospital
according to the criteria of the World Health Organization
[23], and stages were classified according to the tumor,
metastasis, node (TMN) classification of the International
Union Against Cancer [24]. Chest and abdominal com-
puted tomography (CT), magnetic resonance imaging
(MRI) of the brain, bone scintigraphy, and positron-
emission tomography (PET) were performed to examine
the distant metastasis. If CT revealed a mediastinal lymphnode with a short axis-length over 10 mm, mediastinal
staging was performed using video-assisted thoracot-
omy, fine-needle aspiration with bronchoscopy, or PET.
The sites of the N1 and N2 lymph nodes were deter-
mined based on primary tumor location according to
the International Association for the Study of Lung
Cancer using the new lymph node map for NSCLC
[25]. Skip N2 metastases were defined as N2 lymph
node metastases without N1 node involvement. Histo-
pathologic evaluations were done by microscopic exam-
inations of hematoxylin and eosin staining. Proportion
of ground-glass opacity (GGO) area was calculated as
follows:
ð Area on lung window ‐ Area on solid windowð Þ
=Area on lung windowÞ  100:
Preoperative serum concentrations of carcinoembryonic
antigen (CEA), cytokeratin 19 fragment (CYFRA21-1),
and sialyl-Lewis X (SLX) were measured in each patient.
Institutional review board approval and informed consent
This study was approved by the ethics committee at Osaka
City University Graduate School of Medicine. Written in-
formed consent was received from all patients.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism, version 5 (GraphPad Software, San Diego, CA,
USA) and JMP, version 9 (SAS Institute, Cary, NC,
USA). Differences in serum levels of CEA, CYFRA21-1,
and SLX were analyzed for statistical significance using a
nonparametric test (Mann–Whitney U-test). Receiver
operating characteristic (ROC) curve analysis was used
to determine the optimal cutoff point and the sensitivity
and specificity of each tumor marker to distinguish skip
N2 patients from patients without pathological lymph
node metastasis (pN0). The area under the ROC curve
(AUC) was calculated. Statistical significance of the asso-
ciations between skip N2 and various clinicopathological
variables was evaluated using univariate analysis and
multivariate logistic regression analysis. Survival curves
were calculated from the day of surgery to death or to
final follow up using the Kaplan-Meier method, and dif-
ferences in survival curves were assessed with the log-
rank test. P-values <0.05 were considered statistically
significant.
Results
Postoperative survival of patients with different
pathological N factors
The 279 patients with NSCLC included 230 patients
without pathological lymph node metastasis (pN0), 17
patients with hilar or interlobar lymph node metastasis
Figure 1 Kaplan-Meier curves for postoperative overall survival
of 230 pathologic (p)N0 patients, 17 pN1 patients, 12 skip N2
patients, and 20 non-skip N2 patients. The prognosis of skip N2
patients was significantly better than that of non-skip N2 patients
(P = 0.008). There was no significant difference between the prognosis
of skip N2 and pN0 or pN1 patients (P = 0.801, P = 0.985, respectively).
pN0: pathological N0; pN1: pathological N1.
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tients with non-skip N2 metastasis. Table 1 shows
pathological stages of patients based on each patho-
logical N factor. The median postoperative observation
time was 47 months (range 2 to 148 months). The over-
all 5-year survival rates for patients with pN0, pN1, skip
N2, and non-skip N2 were 86.7%, 82.4%, 78.6%, and
44.9%, respectively (Figure 1). The prognosis of skip N2
patients was significantly better than that of non-skip
N2 patients (P = 0.018). There were no significant differ-
ences between the prognoses of skip N2 and pN0 or
pN1 patients (P = 0.336, P = 0.700, respectively).
Distributions of serum CEA, CYFRA21-1, and SLX in pN0
and skip N2 patients
To avoid underestimating skip N2 metastasis with frozen-
section examination of only hilar and interlobar lymph
nodes, clinical and surgical features of pN0 and skip N2
patients were compared. Table 2 shows the mean serum
concentration of CEA, CYFRA21-1, and SLX in pN0 and
skip N2 patients. Serum concentrations of CEA and
CYFRA21-1 were not significantly different between the
two groups (P = 0.196, P = 0.936, respectively). As shown
in Figure 2, serum concentration of SLX rose with in-
creasing pathological N factor. The serum SLX levels in
skip N2 patients (mean 28.0 U/mL) and non-skip N2 pa-
tients (mean, 33.6 U/mL) were significantly higher than in
pN0 patients (mean, 22.9 U/mL; P = 0.015, P = 0.001, re-
spectively). There was no significant difference between
the serum SLX levels of pN1 (mean 25.1 U/mL) and pN0
patients (P = 0.226). The ROC curve of SLX concentration
to distinguish skip N2 patients from pN0 patients is
shown in Figure 3. The AUC was 0.710. The calculated
optimal cutoff point for serum SLX level was 21.4 U/mL
(Youden index = 0.433). The sensitivity of this cutoff was
91.7% (11 of 12 skip N2 patients), and the specificity was
51.7% (109 of 211 pN0 patients). ROC curve analysis of
CEA levels was also performed. The AUC was 0.611, the
optimal cutoff point was 2.8 ng/mL, and the sensitivity
and specificity were 91.7% and 37.3%, respectively. There
was no significant difference between the AUC of SLX













IA/IB 189/31 0/0 0/0 0/0
IIA/IIB 0/4 17/0 0/0 0/0
IIIA 6 0 12 20Clinicopathological features of 12 skip N2 patients
Table 3 shows clinicopathological features of 12 skip N2
patients according to age, sex, tumor side, tumor loca-
tion, histology, tumor size, proportion of GGO, distance
from tumor to pleura on CT, serum concentration of
SLX, lymph vessel invasion (ly) factor, venous invasion
(v) factor, pathological pleural invasion (pPL) factor, and
site of skip N2 metastasis. Of 12 patients with skip N2,
10 (83.3%) were positive for ly factor, and 5 (41.7%)
were positive for v factor, whereas among pN0 patients,
only 20.2% were positive for ly factor and 3.8% for v
factor (P <0.001). On preoperative CT, eight of twelve
skip N2 patients had peripheral lung cancers located
close to the pleura (distance ≤5 mm). Six patients (50%)
had lung cancer in the lower lobes; of these, three had
skip metastasis to subcarinal lymph nodes and three
had skip metastasis to upper mediastinal lymph nodes.
By contrast, all six patients with lung cancer in the
upper lobes had skip metastasis to upper mediastinal
lymph nodes. In relation to the site of skip N2 metasta-
sis, nine patients (75%) had single-station disease, and
three patients (25%) had multi-station disease.
Clinical and surgical features of pN0 and skip N2 patients
To reveal preoperative and intraoperative predictive fac-
tors for skip N2, we compared pN0 and skip N2 patients,
looking for underestimation of nodal factors based on in-
traoperative hilar or interlobar lymph node examination.
Table 4 lists the clinical and surgical features of 230 pN0
patients and 12 skip N2 patients according to age, sex,
tumor side, tumor location, histology, tumor differenti-
ation, tumor diameter, sPL factor, serum SLX concentra-
tion, and serum CEA concentration. Univariate analysis
revealed that skip N2 was significantly associated with
elevated serum SLX concentrations (odds ratio = 9.91;
Figure 2 Percentile distribution of serum sialyl Lewis X (SLX)
concentrations in pathological (p)N0, pN1, skip N2, and non-skip
N2 patients with clinical stage IA non-small cell lung cancer
(NSCLC). Each box contains the variable distribution between the 25th
and 75th percentiles, with median value indicated with a line in the
box. The bars extending above and below the box indicate the 90th
and 10th percentiles, respectively. The mean SLX concentration was
significantly higher in the skip N2 patients compared to that in the
pN0 patients (P = 0.015).
Table 2 Serum concentrations of CEA, CYFRA21-1, and SLX in pN0 and skip N2 patients
Number of patients Mean serum level (95% CI) P-value
Pathological N0 Skip N2 Pathological N0 Skip N2
CEA (ng/mL) 230 12 5.3 (4.5, 6.0) 5.4 (3.5, 7.4) 0.196
CYFRA21-1 (ng/mL) 219 12 1.4 (1.3, 1.6) 1.8 (0.6, 2.9) 0.936
SLX (U/mL) 211 12 22.9 (21.7, 24.1) 28.0 (23.5, 32.6) 0.015
CEA: carcinoembryonic antigen; CYFRA: cytokeratin 19 fragment; SLX: sialyl Lewis X Mann-Whitney U-test
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the two groups in other clinical or surgical features. Re-
sults of multivariate analysis show that SLX was the only
independent predictor of skip N2 metastasis in patients
with c-stage IA NSCLC (odds ratio = 9.43; P = 0.006).
Discussion
Radical segmentectomy with systematic lymph node dis-
section has been performed for small-sized NSCLC
[7,8,14,15]. When intraoperative frozen-section examin-
ation of hilar or interlobar lymph node reveals metasta-
sis, we believe segmentectomy should be converted to
standard lobectomy. The question of whether radical
segmentectomy allows adequate lymph node dissection
remains controversial, because the mean number of dis-
sected lymph nodes with segmentectomy is significantly
lower than with lobectomy [7]. Intraoperative frozen-
section examination of hilar or interlobar lymph can de-
tect pN1 or non-skip N2 disease, which leads to appro-
priate surgical resection. However, underestimation of
skip N2 due to the difficulty of examining all mediastinal
lymph nodes intraoperatively leads to challenges in
choosing the appropriate surgical procedure. In a study
on intraoperative sentinel lymph node identification,
Kim et al. reported that five of forty c-stage I NSCLC
patients (12.5%) had mediastinal sentinel lymph nodes
without hilar lymph node involvement [26]. One mech-
anism of skip N2 is lymphatic flow from the lung dir-
ectly to the mediastinum through the pleura [27].
Radical segmentectomy for patients with skip N2 metas-
tasis has the possibility that micro cancer cells remain in
pleural lymphatic ducts. Therefore, a preoperative or in-
traoperative predictive factor for skip N2 metastasis is
necessary to choose adequate surgical resection.
Skip metastasis to mediastinal lymph nodes has been
reported to occur in 20 to 40% of patients with N2
NSCLC [4,27,28]. In our study, the 5-year survival rate
for skip N2 patients was even higher than that in other
previous reports [17-22], which was because these previ-
ous reports included many patients with large-sized
tumor (tumor diameter >3 cm) [18,20-22]. In addition, 75%
of skip N2 patients had single-station disease, which was
more frequent than the other reports [21,22] and affected
this discrepancy. In several reports, clinicopathologicalfactors were analyzed in patients with skip N2 metastasis.
Skip N2 metastasis was more frequent with tumors in the
upper lobes than the lower lobes [17,18], in right-sided le-
sions than left-sided lesions [21], and in cases of squamous
cell carcinoma than in cases of adenocarcinoma [21,22]. In
our study, there were no significant differences between
pN0 and skip N2 patients in tumor side, location, or hist-
ology. Small-sized NSCLCs are heterogenous, including
pure GGO, GGO with small consolidation and real consoli-
dation. The proportion of GGO area on CT has been re-
ported as a predictor of lymph node metastasis. There has
been shown to be no lymph node metastasis in patients
with c-stage IA adenocarcinoma with more than 50%
proportion of GGO [29]. In addition, 98.7% of patients with
c-stage IA NSCLC with less than 25% consolidation of
the maximum tumor diameter showed pathological
non-invasiveness [30]. In our study, the patients with
c-stage IA NSCLC with more than a 75% proportion of
Figure 3 Receiver operating characteristic curve for serum sialyl
Lewis X (SLX) in pathological (p)N0 and skip N2 patients. The area
under the curve (AUC) = 0.710. The calculated optimal cutoff point for
serum SLX concentration was 21.4 U/mL (Youden index = 0.433), and
the sensitivity was 91.7% (11 of 12 skip N2 patients), whereas the
specificity was 51.7% (109 of 211 pN0 patients).
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a 50 to 75% proportion of GGO occasionally exhibited
skip N2 metastasis, as shown in Table 3.
Pathological factors such as pleural invasion [31] and
tumor size [18] have also been reported to be associated
with skip N2. There were no significant associations be-
tween skip N2 metastasis and surgical or pathological
PL factor or tumor diameter in this study. One mechan-
ism of skip N2 is pleural lymphatic flow [27], and ly and
v factors have been reported to predict lymph node me-











1 73/M Rt Upper Sq 15 19
2 34/F Rt Upper Ad 16 68
3 70/F Rt Upper Ad 21 47
4 62/F Rt Upper Ad 14 24
5 71/M Rt Lower Ad 30 9
6 61/F Rt Lower Ad 24 27
7 60 M Rt Lower Ad 24 23
8 62/F Lt Upper Ad 20 72
9 81/M Lt Upper Sq 27 13
10 63/M Lt Lower Ad 15 38
11 60/M Lt Lower Ad 23 7
12 57/F Lt Lower Ad 20 3
Pt. no., patient number; M,male; F, female; Rt, right; Lt, left; Ad, adenocarcinoma; Sq
sured on computed-tomography; SLX, sialyl Lewis X; ly, lymph vessel invasion facto
upper paratracheal lymph node; No. 4R LN, lower paratracheal lymph node; No. 5 Lwhether distance to pleura or intersegmental plane, ly
factor, or v factor were important predictors of skip N2
metastasis. Our data support distance to pleura, ly factor,
and v factor as risk factors for skip N2 metastasis as
shown in Table 3. Eight of twelve patients with skip N2
metastasis had peripheral lung cancers located close to
the pleura (distance ≤5 mm), and eleven of twelve
were positive for either ly or v factor. The only case
of skip N2 that was close to the pleura and was nega-
tive for both ly and v factors was the largest tumor
in the group (30 mm). Although ly and v factors were
significantly associated with skip N2, it is important
to note that these factors cannot be assessed pre-
operatively or intraoperatively. In our study, serum
SLX concentration was the only useful preoperative
or intraoperative test to help predict skip N2.
SLX is a carbohydrate antigen adhesion molecule that
has been used as a tumor marker for carcinoma of many
organs, including the lungs [33]. SLX plays an important
role in cell-cell recognition and is therefore thought to
be associated with the metastatic ability of cancer cells.
In the case of lung cancer, we have reported that high
serum concentrations of SLX are predictive of lymph
node metastasis, postoperative recurrence, and poor
prognosis in patients with NSCLC [34-36]. Several au-
thors have reported that SLX is predictive of distant me-
tastasis in patients with primary lung cancer [37-39]. As
for other tumor markers, high serum CEA has also been
reported to be a predictive factor for lymph node metas-
tasis in patients with small-sized adenocarcinoma of the
lung [40]. Although the AUC for SLX was 0.710, which




ly v pPL Site of skip
N2
4 36.2 + - 0 No. 2R, 4R LN
13 27.4 + - 0 No.4R LN
30 21.4 + + 0 No.2R, 4R LN
28 13.1 + - 0 No. 4R LN
0 40.2 - - 0 No. 7 LN
0 32.8 + + 1 No. 7 LN
0 29.0 + + 0 No.2R, 4R LN
5 23.6 + + 1 No. 5 LN
0 24.5 + - 2 No. 5 LN
0 28.0 + - 0 No. 5 LN
14 27.0 - + 0 No. 7 LN
0 33.0 + - 0 No. 5 LN
, squamous cell carcinoma; GGO, ground-glass opacity; distance to pleura, mea-
r; v, venous invasion factor; pPL, pathological pleural invasion factor; No. 2R,
N, subaortic lymph node; No. 7 LN, subcarinal lymph node.
Table 4 Clinical and surgical features of 230 pathological (p)N0 patients and 12 skip N2 patients
Number of patients Univariate Multivariate
pN0 Skip N2 P-value P-value Odds ratio 95% CI
Age
Mean ± SD 66.5 ± 10.2 62.8 ± 11.4 0.268a
Sex
Male 121 6 1.000 NA NA NA
Female 109 6
Side
Right 131 7 1.000 NA NA NA
Left 99 5
Location
Upper/Middle lobe 151 6 0.353 NA NA NA
Lower lobe 79 6
Histology
Ad 192 10 1.000 NA NA NA
Sq/AdSq 38 2
Tumor differentiation
Well/moderate 181 7 0.146 0.361 1.80 0.49, 6.13
Poor 49 5
Tumor diameter (cm)
≤2 113 6 1.000 NA NA NA
>2 117 6
sPL factor
sPL0 141 6 0.547 NA NA NA
sPL1-3 89 6
SLX (U/mL)
≥21.4 121 11 0.007 0.006 9.43 1.75, 175
<21.4 109 1
CEA (ng/mL)
≥2.8 143 11 0.060 0.077 4.78 0.87, 89.2
<2.8 87 1
Ad: adenocarcinoma Fisher’s exact test Multivariate logistic regression analysis
Sq: squamous cell carcinoma aMann-Whitney U-test
AdSq: adenosquamous carcinoma
sPL factor: surgical pleural invasion factor
CI: confidence interval
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gistic regression analysis showed serum SLX concen-
tration was an independent predictive factor for skip
N2 in patients with c-stage IA NSCLC. The calcu-
lated optimal cutoff point for serum SLX concentra-
tion in this study (21.4 U/mL) was lower than the
accepted cutoff for cancer screening (38.0 U/mL).
We propose that the prognosis cutoff value should
be used to predict skip N2 metastasis rather than the
diagnosis cutoff value.Conclusions
We found that serum SLX concentration was an inde-
pendent predictive factor for skip N2 in c-stage IA
NSCLC. Skip metastasis is common in NSCLC patients
with high serum SLX, and lobectomy with complete dis-
section of hilar and mediastinal lymph nodes should re-
main the standard surgical procedure for these patients.
Preoperative serum SLX levels have the possibility to
change the present surgical procedure of segmentectomy
for patients with c-stage IA NSCLC.
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